Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC ...

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...